These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 215528)

  • 21. Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma.
    Foong YT; Cheng HM; Sam CK; Dillner J; Hinderer W; Prasad U
    Int J Cancer; 1990 Jun; 45(6):1061-4. PubMed ID: 1693600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [IgG and IgA antibodies to the Epstein-Barr virus and nasopharyngeal carcinoma].
    Vera Sempere FJ
    Med Clin (Barc); 1992 May; 98(19):758-9. PubMed ID: 1318986
    [No Abstract]   [Full Text] [Related]  

  • 24. Serum anti-EBV IgA is inversely related to tumor infiltration by surface IgA positive lymphocytes in nasopharyngeal carcinoma.
    Gunvén P; Klein G; Henle W; Henle G; Forsby N
    Biomed Pharmacother; 1983; 37(1):41-4. PubMed ID: 6311307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serological and immunohistological assessment of Epstein-Barr virus infection in Sicilian patients with suspected nasopharyngeal carcinoma.
    Ammatuna P; de Thè G; Speciale R; Sammartano F; Arista S; Zerillo G
    Microbiologica; 1988 Apr; 11(2):89-94. PubMed ID: 2841559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Significance of virus-specific antibodies to EBV-antigens in patients with nasopharyngeal carcinoma (author's transl)].
    Wilmes E; Wolf H; Deinhardt F; Naumann HH
    Laryngol Rhinol Otol (Stuttg); 1979 Dec; 58(12):911-5. PubMed ID: 231716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An immunoperoxidase assay for the detection of specific IgA antibody in Epstein-Barr virus infections.
    Cevenini R; Donati M; Rumpianesi F; Moroni A; Paolucci P
    J Clin Pathol; 1984 Apr; 37(4):440-3. PubMed ID: 6323549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating immune complexes in patients with nasopharyngeal carcinoma.
    Wolf GT; Wolfe RA
    Laryngoscope; 1990 Mar; 100(3):302-8. PubMed ID: 1689798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus is not associated with head and neck neoplasms other than nasopharyngeal carcinoma.
    Kottaridis SD; Goula I; Kiparissiadis P
    Neoplasma; 1982; 29(3):327-31. PubMed ID: 6290911
    [No Abstract]   [Full Text] [Related]  

  • 30. ELISA for the detection of serum and saliva IgA against the BMRFI gene product of Epstein-Barr virus.
    Nadala EC; Tan TM; Wong HM; Ting RC
    J Med Virol; 1996 Sep; 50(1):93-6. PubMed ID: 8890046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies of the Epstein-Barr herpesvirus relationship with Hodgkin's disease and the use of virus immunological markers in differential diagnostics of nasopharyngeal carcinoma.
    Mazurenko NP; Gurtsevich VE; Stepina VN; Plakhov IV
    Arch Geschwulstforsch; 1983; 53(3):253-9. PubMed ID: 6311138
    [No Abstract]   [Full Text] [Related]  

  • 32. Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma and in comparison groups.
    Neel HB; Pearson GR; Taylor WF
    Ann Otol Rhinol Laryngol; 1984; 93(5 Pt 1):477-82. PubMed ID: 6093669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr-specific IgA in nasopharyngeal cancer.
    Lancet; 1978 Jun; 1(8078):1345-6. PubMed ID: 78104
    [No Abstract]   [Full Text] [Related]  

  • 34. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
    Mazeron MC
    Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Epstein-Barr virus--a clinically relevant feature of nasopharyngeal carcinoma? (author's transl)].
    Wilmes E; Wolf H; Deinhardt F; Naumann HH
    Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):4-6. PubMed ID: 6261051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence areas.
    de-The G; Lavoue MF; Muenz L
    IARC Sci Publ (1971); 1978; (20):471-81. PubMed ID: 215529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody patterns following therapy.
    Henle W; Ho JH; Henle G; Chau JC; Kwan HC
    Int J Cancer; 1977 Nov; 20(5):663-72. PubMed ID: 200569
    [No Abstract]   [Full Text] [Related]  

  • 38. Serum IgA antibodies to Epstein-Barr virus capsid antigen preceding symptoms of nasopharyngeal carcinoma.
    Ho HC; Kwan HC; Ng MH; de The G
    Lancet; 1978 Feb; 1(8061):436. PubMed ID: 75457
    [No Abstract]   [Full Text] [Related]  

  • 39. [A modified 131 I immuno-autoradiographic method for detection of serum EB virus VCA-IgA antibody in nasopharyngeal carcinoma].
    Shang M
    Zhonghua Zhong Liu Za Zhi; 1982 Nov; 4(4):262-4. PubMed ID: 6299669
    [No Abstract]   [Full Text] [Related]  

  • 40. Neutralizing EBV-specific IgA in throat washings of nasopharyngeal carcinoma (NPC) patients.
    Desgranges C; De-Thé G; Ho JH; Ellouz R
    Int J Cancer; 1977 May; 19(5):627-33. PubMed ID: 193801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.